GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » EPS (Basic)

NovMetaPharma Co (XKRX:229500) EPS (Basic) : ₩-1,201.00 (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co EPS (Basic)?

NovMetaPharma Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was ₩-1,201.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,201.00.

NovMetaPharma Co's EPS (Diluted) for the six months ended in Dec. 2023 was ₩-1,201.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,201.00.

NovMetaPharma Co's EPS without NRI for the six months ended in Dec. 2023 was ₩-753.63. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -753.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


NovMetaPharma Co EPS (Basic) Historical Data

The historical data trend for NovMetaPharma Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co EPS (Basic) Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -1,402.00 -736.00 -787.00 -638.00 -1,201.00

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only -1,402.00 -736.00 -787.00 -638.00 -1,201.00

NovMetaPharma Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

NovMetaPharma Co's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-12555.185-0)/10.454
=-1,200.99

NovMetaPharma Co's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-12555.185-0)/10.454
=-1,200.99

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,201.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovMetaPharma Co  (XKRX:229500) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


NovMetaPharma Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines